Early studies indicate up to 20 – 24 percent of Covid-19 patients can experience myocardial injury or heart failure.
Newark, CA – USA | December 03, 2020 –(Press Release Wire)– Ziosoft, a pioneer in 3D/4D AI medical visualization, is featuring its comprehensive suite of advanced visualization and post-processing applications, on a true vendor neutral platform, at RSNA’s virtual 2020 exhibition being held November 29 – December 5. Featured this year on the company’s flagship Ziostation2 system are a wide-range of applications, which are well suited in the analysis of pathology caused by the Covid-19 virus as the disease affects multiple anatomy, such as respiratory, pulmonary and cardiovascular sites.
Several studies published earlier this year indicate Covid-19 specifically can cause myocardial injury or heart failure in up to 20 – 24 percent of affected patients. Two of these studies found that between 49-52 percent of patients who died from the disease experienced heart failure.
“In addition to respiratory and pulmonary impact, these recent studies demonstrate significant cardiac injury risk as well,” said Rajeev Taitriya, vice president of Business Development and Marketing, Ziosoft. “Our Ziostation2 software provides numerous tools for analyzing these symptoms including pulmonary analysis, virtual bronchoscopy, CT cardiac function and MR coronary analysis, in addition to several other visualization and measurement solutions. All are designed to provide comprehensive analysis capabilities to help support diagnostic confidence and help guide therapeutic endeavors.”
Ziosoft’s platform provides a robust and clinically validated algorithm, which is driven by both a traditional and new era of machine learning, unlocking the potentials of artificial intelligence (AI) for efficient and repeatable outcomes. The company’s flagship Ziostation2 is an economical and scalable multi-departmental solution. A full suite of regulatory cleared 2D, 3D, and 4D analytical tools provides consistent functionality across the enterprise, without compromise.
With over 3,000 installations in 2,000 locations throughout more than 30 countries globally, the company is also highlighting PhyZiodynamics™ in Vivo, which enables virtual dynamic dissection to support precise therapy for organ targeting analyses and Implantations. PhyZiodynamics in Vivo offers an unprecedented “real-time” journey through the body non-invasively, supporting diagnoses and treatment planning for numerous anatomical targets.
“These unprecedented times call for highly sophisticated and comprehensive solutions for imaging visualization and analysis,” said Shusuke Chino, co-founder and president, Ziosoft. “We use 20 plus years of medical imaging expertise with deep learning to enable accurate segmentation with easy-to-use intuitive tools for efficient and customizable workflows. This experience has not only brought outstanding 3D/4D to the radiological community, but several other useful tools to support clinicians during this challenging period.”
Press & Media Contact:
+1 (650) 248-9081